Please login to the form below

Not currently logged in
Email:
Password:

cardiomyopathy

This page shows the latest cardiomyopathy news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

placebo in patients with ATTR cardiomyopathy, reducing the death rate from around 43% to 29.5%. ... The drug has also been approved for the cardiomyopathy indication in Japan, Brazil and Canada.

Latest news

  • Vyndaqel a bright spot as Pfizer comes under pressure Vyndaqel a bright spot as Pfizer comes under pressure

    following its FDA approval to treat ATTR cardiomyopathy last September. ... As of the end of 2019 more than 9, 000 ATTR cardiomyopathy patients had been diagnosed in the US – raising the diagnosis rate from 1% pre-Vyndaqel launch to around 9%,

  • Alnylam gains key NICE approval for Onpattro Alnylam gains key NICE approval for Onpattro

    approval for patients with the cardiomyopathy (CM) subtype of transthyretin-mediated amyloidosis (ATTR), with European approval set to follow shortly.

  • Pfizer buys dwarfism drug company Therachon for $810m Pfizer buys dwarfism drug company Therachon for $810m

    The deal adds to Pfizer’s rare disease portfolio, which just chalked up a major success with the approval of tafamidis products Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM)

  • Speedy approval for Pfizer's Onpattro rival Speedy approval for Pfizer's Onpattro rival

    Approved in two different formulations. Pfizer’s blockbuster-in-waiting drug tafamidis has gained FDA approval to treat cardiomyopathy in patients with rare disease ATTR. ... However Alnylam is preparing to launch its APOLLO-B phase 3 study to support

  • Solid Q1 results lift Pfizer as it waits for pipeline boost Solid Q1 results lift Pfizer as it waits for pipeline boost

    That will come on the back of product launches like tafamidis in rare disease transthyretin amyloid cardiomyopathy, a trio of recently-approved cancer drugs including Vizimpro (dacomitinib), a rival to

More from news
Approximately 3 fully matching, plus 25 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Jonathan Fox leaves AstraZeneca for MyoKardia Jonathan Fox leaves AstraZeneca for MyoKardia

    MyoKardia's genetically targeted approach and cutting-edge platform has the potential to fundamentally change the lives of patients with hypertrophic cardiomyopathy and dilated cardiomyopathy,” he said.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...

Infographics